Logo 20png


Biodegradable Gold Nanoparticles To Diagnose And Treat Cancer

  • Stage Product In Development
  • Industry Biotechnology
  • Location Philadelphia, PA, US
  • Currency USD
  • Founded May 2015
  • Employees 3
  • Incorporation Type LLC
  • Website polyaurum.com

Company Summary

PolyAurum is a pre-clinical stage biotechnology company focused on developing and commercializing biodegradable gold nanoparticles (BGNP) for diagnostic and therapeutic indications including cancer. Enhancement of radiotherapy with BNGPs has the potential to increase cancer-free survival and improve patient quality of life.


  • Dsc 0252
    President and Chief Executive Officer

    Debra has a 30+ year career as an accomplished strategic healthcare executive and entrepreneur with diverse and progressive product development and commercialization experience in global pharmaceutical and biomedical companies, including Centocor, GSK, Endo Pharmaceuticals and IMS Health.

  • 86204e1f 3e72 4683 a167 59cf8cc310ad

    Dr. David Cormode, PhD is Assistant Professor of Radiology at the University of Pennsylvania's Perleman School of Medicine. He has over 10 years of experience in the synthesis and development of nanoparticles. He is a co-founder of PolyAurum.

  • 9f4d09c0 9821 4a9a 9619 c14be7749803

    Dr. Andrew Tsourkas, PhD is Professor of Bioengineering at the University of Pennsylvania. He has over 15 years of experience in the development of nanoparticle medicines and is co-founder of 4 start-up biotechnology companies including PolyAurum.

  • Dors3074 20 1

    Dr. Jay Dorsey, MD, PhD is Assistant Professor of Radiation Oncology at the University of Pennsylvania's Perleman School of Medicine. He is an expert in the development of novel radiotherapeutics and co-founder of 2 oncology-focused start-up companies including PolyAurum.

  • 19b199e8 3140 46f4 bcf6 b7e226c3ed8e

    Dr. Rabe'e Cheheltani, PhD served as the teams entrepreneurial lead. She is a Postdoctoral Fellow in Radiology at the University of Pennsylvania's Perleman School of Medicine. She has 2 years of experience in developing and characterizing gold/biodegradable polyphosphazene nanoparticle formulations. She is a co-founder of PolyAurum.

  • A5acfe26 bc20 4457 b77d a9acd0e18038
    Chief Scientific Officer

    Dr. Thais Sielecki, PhD is Chief Scientific Officer. She has more than 20 years of experience in drug development for large pharmaceutical companies such as Bristol Myers Squib and DuPont Merck and mid-sized companies such as Cytokine Pharmasciences. She has expertise in early development taking pharmaceutical assets from preclinical development through Phase II clinical studies.

  • 303b7ee2 9655 4001 9e56 5fe6dddc607c
    Director of Product Development

    Dr. Neha Saxena, PhD is Director of Product Development. She has responsibility for optimization and characterization of PolyAurum’s biodegradable gold nanoparticles. Dr Saxena has a broad background in biomaterials, including biodegradable hydrogel-based scaffolds for articular cartilage tissue engineering, nanoparticle-based tumor targeting and ablation, optimization of collagen mineralization process for bone and dental repair applications.


  • Default avatar
    Andrew Hamilton, Morgan Lewis
    Default avatar
    Nicolette Sifontis, Stephano Slack - Accounting